Effects of ultrasound on apoptosis induced by anti-CD20 antibody in CD20-positive B lymphoma cells

被引:10
|
作者
Danno, Daisuke [1 ]
Kanno, Masatoshi [1 ]
Fujimoto, Shinichi [1 ]
Feril, Loreto B., Jr. [2 ]
Kondo, Takashi [3 ]
Nakamura, Shinobu [1 ]
机构
[1] Nara Med Univ, Sch Med, Dept Gen Med, Kashihara, Nara 634, Japan
[2] Fukuoka Univ, Sch Med, Dept Anat, Fukuoka 81401, Japan
[3] Toyama Univ, Dept Radiol Sci, Grad Sch Med & Pharmaceut Sci, Toyama 930, Japan
关键词
ultrasound; rituximab; antigen-antibody reaction; immunotherapy; B-cell lymphoma;
D O I
10.1016/j.ultsonch.2007.08.004
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
Aim: The present study was conducted to examine the thermal and non-thermal effects of ultrasound on apoptosis induced by anti-CD20 monoclonal antibody (rituximab). Materials and methods: SU-DHL-4 cells, a CD20-positive cell line derived from B cell lymphomas with a BCL2 gene rearrangement, were exposed to continuous 1 MHz ultrasound for therapeutic use under an air- or CO2-saturated condition to control cavitation. Early apoptosis (EA) and secondary necrosis (SN) were examined by flow cytometry. Cavitation was determined by detecting the hydroxyl radicals derived from pyrolysis of water molecules using electron paramagnetic resonance-spin trapping. To assess thermal effects, cells were treated in a temperature-controlled water bath. Results: There was a significant additive increase in EA and EA + SN observed in cells treated with rituximab combined with heat at 42 degrees C or non-thermal ultrasound at 0.5 W/cm(2) under an air-saturated condition, where heat or ultrasound induced some cell death. A significant synergistic increase in EA and EA + SN was observed in cells treated with rituximab and ultrasound at 2.5 W/cm(2) under CO2-saturated conditions, where inertial cavitations were completely suppressed. No enhancement was observed at a temperature less than 40 degrees C or ultrasound at 0.5 W/cm2 under CO2-saturated conditions. Conclusion: These results suggest that the immuno-therapeutic application of ultrasound at relatively high-intensities combined with rituximab thus produces synergistic effects under conditions where the non-thermal and non-cavitational effects are predominant. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:463 / 471
页数:9
相关论文
共 50 条
  • [1] Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody
    Taji, H
    Kagami, Y
    Okada, Y
    Andou, M
    Nishi, Y
    Saito, H
    Seto, M
    Morishima, Y
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1998, 89 (07): : 748 - 756
  • [2] Monoclonal anti-CD20 antibody rituximab (rituxan) for treatment of CD20-positive Hodgkin's lymphoma: The German experience.
    Rehwald, U
    Engert, A
    Diehl, V
    [J]. BLOOD, 2000, 96 (11) : 729A - 729A
  • [3] BLOCKING B-CELLS (ANTI-CD20/ANTI-CD20)
    Isenberg, David A.
    [J]. RHEUMATOLOGY, 2015, 54 : 1 - 1
  • [4] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Gui, Lin
    Han, Xiaohong
    He, Xiaohui
    Song, Yuanyuan
    Yao, Jiarui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Zhang, Shuxiang
    Zhang, Weijing
    Gai, Wenlin
    Xie, Liangzhi
    Shi, Yuankai
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (02) : 197 - 208
  • [5] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Lin Gui
    Xiaohong Han
    Xiaohui He
    Yuanyuan Song
    Jiarui Yao
    Jianliang Yang
    Peng Liu
    Yan Qin
    Shuxiang Zhang
    Weijing Zhang
    Wenlin Gai
    Liangzhi Xie
    Yuankai Shi
    [J]. Chinese Journal of Cancer Research, 2016, (02) : 197 - 208
  • [6] Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl
    Culic, Srdana
    Kuzmic, Ivana
    Pranic-Kragic, Ankica
    Jankovic, Stipan
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2006, 23 (08) : 661 - 666
  • [7] Which Anti-CD20 Antibody Is Better in Follicular Lymphoma?
    Armitage, James O.
    Longo, Dan L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (14): : 1389 - 1390
  • [8] MODULATION OF CD20 EXPRESSION ON B CELLS BY ANTI-CD20 ANTIBODIES
    Bellintani, Elaine C.
    de Marco, Renato
    Fantini, Renata
    Valim, Tiago
    Macedo, Denise
    Miyamoto, Yuriko
    Temin, Julia
    Gerbase-DeLima, Maria
    [J]. HUMAN IMMUNOLOGY, 2016, 77 : 138 - 138
  • [9] Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
    Lu, Chia-Yen
    Chen, Gregory J.
    Tai, Pei-Han
    Yang, Yu-Chen
    Hsu, Yu-Shen
    Chang, Mingi
    Hsu, Chuan-Lung
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 473 (04) : 808 - 813
  • [10] Real Time Analysis of Binding between Rituximab (Anti-CD20 Antibody) and B Lymphoma Cells
    Tan, Liang
    Lin, Peiling
    Chisti, Mohammad M.
    Rehman, Abdul
    Zeng, Xiangqun
    [J]. ANALYTICAL CHEMISTRY, 2013, 85 (18) : 8543 - 8551